Table 3.
Rapid viral response |
Undetectable or VL ≤15 UI |
|||||
---|---|---|---|---|---|---|
OR | 95% CI | p Value | OR | 95% CI | p Value | |
Treatment initiation (Season A vs Season B) | 2.03 | 1.27 to 3.25 | 0.003 | 1.93 | 1.14 to 3.29 | 0.014 |
Type of therapy (lead-in no vs yes) | 23.70 | 10.66 to 52.69 | <0.0001 | 90.1 | 46.54 to 174.6 | <0.0001 |
HCV RNA (≤600 000 vs >600 000 IU/mL) | 2.14 | 1.29 to 3.55 | 0.003 | 4.66 | 2.36 to 9.17 | <0.0001 |
IL-28 polymorphism (CC vs no CC) | 1.94 | 1.14 to 3.30 | 0.014 | 2.24 | 1.17 to 4.29 | 0.015 |
Naïve vs experienced | 1.55 | 0.91 to 2.63 | 0.10 | 0.74 | 0.41 to 1.31 | 0.30 |
Genotype (1b vs 1a) | 1.32 | 0.73 to 2.40 | 0.35 | 0.71 | 0.37 to 1.36 | 0.30 |
Diabetes mellitus (no vs yes) | 1.28 | 0.63 to 2.61 | 0.49 | 1.42 | 0.66 to 3.05 | 0.36 |
Age (≥50 vs <50 years) | 0.92 | 0.55 to 1.52 | 0.75 | 1.01 | 0.58 to 1.78 | 0.95 |
Fibrosis (≥F3 vs <F3) | 0.92 | 0.51 to 1.66 | 0.79 | 1.63 | 0.80 to 3.30 | 0.17 |
HCV, hepatitis C virus; VL, viral load.